Cannabis Science, Inc. (CBIS)

cannabis_print_logoCannabis Science, Inc. is a patient-oriented biotech company that specializes in cannabis formulation-based drug development and consulting. It is dedicated to meeting the needs of the community with products that are based on cannabinoid science. With the company’s unique understanding of metabolic processes, it aims to provide innovative treatment options for people whose medical needs were unmet.

As one of the longest standing companies in the cannabis industry, Cannabis Science continues to provide products that are medical cannabinoid formulations. The company is committed to providing those in need of new treatments for debilitating and life-threatening conditions with access to high-quality cannabinoid pharmaceuticals, and advocating their rights.

Cannabis Science works with drug development experts, as wells as clinical research and medical characteristic experts to develop, manufacture, and commercialize cannabinoid-based therapeutic approaches that can help treat many different types of critical ailments, including age-related medical conditions, neurobehavioral disorders, infections, and cancer. The company also works closely with regulatory agencies in their effort to alleviate suffering and to promote health of patients through cannabinoid science.

Cannabis Science, Inc. is a pioneering biotech company that creates medical cannabinoid formulations developed from cannabinoid compounds, which are derived from the cannabis plant. The material used by the company for clinical trials comes from GMP-compliant cultivation and production facilities. Its immediate focus is to develop treatment for different medical conditions, including certain types of cancer. The company continues to improve its standards to develop cutting edge treatments for cancer and other medical conditions.

Trading in the OTC under the symbol CBIS, Cannabis Science, Inc. is the first and only existing publicly traded biotech company on the market involved in formulations that are based on cannabinoid extracts. As the leader in the industry, the company consults and leads emerging businesses with a preferred business model that can mature into a key business model.


Yahoo! Finance: CBIS News

Latest Financial News for CBIS

Independent Valuation of U.S. Patent Number 9,763,991 for Cannabinol (CBN) Initiated as Cannabis Science Negotiates Licensing and Marketing Deals in Canada and the USA to Develop and Sell CBN Products Utilizing the Company’s Patent

IRVINE, CA, April 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it is in current negotiations to license the Company’s U.S. patent number 9,763,991 for the Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, including Anxiety, Sleep Disorders, PTSD and more. The U.S. market for sleep disorder products alone was estimated at over $28 billion in 2017 and is expected to grow by 3.3% annually.

Elpasso Farms Just Announced South African Health Products Regulatory Authority (SAHPRA) Awarded Elpasso Farms One of the First Medical Cannabis Cultivation Licenses; Cannabis Science Applauds

“Together with Cannabis Science, we have the opportunity to take a leadership position in the medical cannabis industry in South Africa and develop medicines that can help millions of people throughout Africa. We are one of the few companies to qualify for a medical cannabis license in South Africa. Elpasso Farms is positioned to commence the cultivation of medical cannabis to support the Company’s research and development initiatives that are currently underway in South Africa, North America, Europe, and other international jurisdictions.

Cannabis Science Expands Into Canadian Market With Wholly-Owned Subsidiary Cannabis Science Canada Inc., Commences Negotiations for Canadian Land, Licenses, and Expansion Capital

IRVINE, CA, March 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has expanded into the Canadian market with the formation of Cannabis Science Canada, Inc. Cannabis Science Canada Inc. is a wholly-owned subsidiary of Cannabis Science Inc., and has already begun negotiations for Canadian land, licenses, and expansion capital. “We currently have a number of very important research and drug-development initiatives underway in the U.S., Europe, South America, and in Sub-Saharan Africa.

Cannabis Science iCannabinoid Ambassadors Program Appointments Underway; Ambassadors Will Promote Company Initiatives Globally and Help Share Accurate and Reliable Health Information

IRVINE, CA, March 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that today it has launched the selection and appointment process for the Company’s iCannabinoid Ambassador’s Program. One of the most important components of Cannabis Science’s growth and international market penetration strategy is information and the power of the people! The iCannabinoid Ambassador’s Program is expected to help Cannabis Science rapidly expand the Company’s footprint and support the development of new initiatives in new markets. Each iCannabinoid Ambassador will be designated an area of interest and expertise, based on your experience, expertise, and desired level of commitment.

CSE New Listing - Cannabis One Holdings Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com

Vancouver, British Columbia--(Newsfile Corp. - March 1, 2019) -  Cannabis One Holdings (CSE:CBIS) is one of the latest new listing on the Canadian Securities Exchange, having previously traded on the TSX Venture Exchange as Metropolitan Energy Corp., prior to a reverse takeover.For more information, please view the InvestmentPitch Media "video" which provides additional information on the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Cannabis One" in the search box.Cannot ...